1. Mitral Valve Disease

3. This program will include a discussion of off-label treatment with devices not approved by the FDA for use in the US.

4. Mitral Valve Disease Overview

5. Increasing Prevalence of Valvular Heart Disease in the Elderly

6. Prevalence of Mitral Regurgitation in US

7. MVD Is an Extremely Common Disease With a Massive Prevalence-Treatment Gap

8. Practice Gaps Among PCPs, Cardiologists, and Cardiac Surgeons

9. Components of MR Assessment

10. Mitral Regurgitation Etiologies

11. Approach to MR Assessment

12. When to Refer?*

13. Chronic Severe Primary MR

14. CTSNet Trial 2-Year Outcomes

15. CTSNet Trial 2-Year Outcomes (cont)

16. COAPT Trial Design

17. MR in Asymptomatic Patients

18. Active Surveillance in Asymptomatic Patients

19. Stages of Secondary MR

20. Chronic Severe Secondary MR

21. Mitral Valve Anatomic “Sweet Spots”

22. Implantation Process

23. Left Heart Disease

24. Shared Decision Making Favoring Mechanical Prosthesis or Bioprosthesis

25. Early Experience With TMVR

26. Apollo TMVR Trial

27. Apollo TMVR Trial Study Endpoints

28. Indications for Surgery for MR

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)